The relationship between anti-Xa activity and the renal function in elderly patients who are on apixaban

Trial Profile

The relationship between anti-Xa activity and the renal function in elderly patients who are on apixaban

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Apixaban (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 24 Jul 2017 Status changed from recruiting to completed.
    • 22 Jul 2016 Status changed from not yet recruiting to recruiting.
    • 30 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top